Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reiterated by research analysts at Cowen and Company in a research report issued to clients and investors on Thursday. They currently have a $69.00 price objective on the biotechnology company’s stock. Cowen and Company’s price objective indicates a potential upside of 49.29% from the company’s previous close.

Several other analysts have also recently commented on the company. SunTrust Banks, Inc. restated a “buy” rating and issued a $56.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. Piper Jaffray Companies restated an “overweight” rating and issued a $55.00 target price (up from $50.00) on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. Finally, Credit Suisse Group raised their target price on Sarepta Therapeutics from $5.65 to $81.00 and gave the company an “outperform” rating in a research report on Thursday, September 7th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus price target of $62.31.

Sarepta Therapeutics (NASDAQ SRPT) traded up 3.19% during mid-day trading on Thursday, hitting $46.22. The company had a trading volume of 2,221,359 shares. The stock’s 50 day moving average price is $39.38 and its 200 day moving average price is $34.42. Sarepta Therapeutics has a 52-week low of $26.26 and a 52-week high of $63.73. The firm’s market cap is $2.97 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analyst estimates of $22.52 million. During the same quarter in the prior year, the business earned ($1.19) earnings per share. The firm’s revenue was up 350000.0% compared to the same quarter last year. On average, equities research analysts predict that Sarepta Therapeutics will post ($1.23) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Sarepta Therapeutics, Inc. (SRPT) Given “Outperform” Rating at Cowen and Company” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/14/sarepta-therapeutics-inc-srpt-given-outperform-rating-at-cowen-and-company.html.

In other news, CFO Sandesh Mahatme sold 50,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $2,050,000.00. Following the completion of the sale, the chief financial officer now directly owns 41,736 shares of the company’s stock, valued at approximately $1,711,176. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Alexander Cumbo sold 5,918 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the sale, the senior vice president now directly owns 22,793 shares of the company’s stock, valued at $934,513. The disclosure for this sale can be found here. Over the last three months, insiders have sold 78,056 shares of company stock valued at $3,224,208. Corporate insiders own 9.60% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Asymmetry Capital Management L.P. boosted its position in shares of Sarepta Therapeutics by 82.2% in the second quarter. Asymmetry Capital Management L.P. now owns 158,810 shares of the biotechnology company’s stock worth $5,353,000 after buying an additional 71,630 shares during the period. Ameritas Investment Partners Inc. boosted its position in shares of Sarepta Therapeutics by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after buying an additional 271 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of Sarepta Therapeutics by 85.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 20,871 shares of the biotechnology company’s stock worth $704,000 after buying an additional 9,635 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Sarepta Therapeutics by 3.7% in the second quarter. The Manufacturers Life Insurance Company now owns 40,188 shares of the biotechnology company’s stock worth $1,355,000 after buying an additional 1,435 shares during the period. Finally, Osterweis Capital Management Inc. acquired a new stake in shares of Sarepta Therapeutics in the second quarter worth $3,806,000. 65.43% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.